Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 5—May 2004
Research

Multidrug-resistant Tuberculosis in Central Asia

Helen Suzanne Cox*Comments to Author , Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶
Author affiliations: *Médecins Sans Frontières Aral Sea Area Programme, Uzbekistan and Turkmenistan, Tashkent, Uzbekistan; †National Reference Centre for Mycobacteria, Borstel, Germany; ‡Ministry of Health, Nukus, Karakalpakstan, Uzbekistan; §Médecins Sans Frontières, Amsterdam, the Netherlands; ¶World Health Organization, Geneva, Switzerland

Main Article

Table 4

Second-line drug resistance resultsa

New Retreatment MDR-TBb
Total Resistant (%) Total Resistant (%) Total Resistant (%)
Karakalpakstan (Uzbekistan)
Prothionamide 106 7 (7) 107 11 (10) 57 9 (16)
Capreomycin 88 1 (1) 101 1 (1) 56 1 (2)
Ofloxacin 88 2 (2) 101 4 (4) 56 1 (2)
Dashoguz (Turkmenistan)
Prothionamide 105 1 (1) 98 4 (4) 22 2 (9)
Capreomycin 89 0 93 0 21 0
Ofloxacin 89 0 93 0 21 0

aAll strains were tested for prothionamide; a representative subset of these were tested for both capreomycin and ofloxacin.
bMDR-TB, multidrug-resistant tuberculosis.

Main Article

Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external